# Bradykinin Receptor Blocker in ACE Inhibitor-associated Angioedema

> **NCT00517582** · PHASE1 · TERMINATED · sponsor: **Vanderbilt University** · enrollment: 13 (actual)

## Conditions studied

- Angioneurotic Edema

## Interventions

- **DRUG:** HOE-140
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00517582
- **Lead sponsor:** Vanderbilt University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-09
- **Primary completion:** 2011-09
- **Final completion:** 2015-12
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** This study was stopped to allow initiation of a mult-center study
- **Last updated:** 2015-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00517582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00517582, "Bradykinin Receptor Blocker in ACE Inhibitor-associated Angioedema". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00517582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*